A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Disease Sites:

Liver

Staging:

Phase I/II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Atezolizumab, Bevacizumab, Ipilimumab, Pumitamig

Principal Investigator(s):

Heumann, Thatcher

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

04-30-2026

Trial Type:

Treatment

Protocol ID:

VICCGIP25073

National Clinical Trial ID:

NCT07291076

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

ALL

Accepts Healthy Volunteers?:

false

Inclusion Criteria:

Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).

Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Participants must have no prior systemic therapy for advanced/ unresectable HCC.

Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Exclusion Criteria:

Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence.

Participants must not have an organ transplant or autoimmune disease.

Other protocol-defined Inclusion/Exclusion criteria apply.

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Eligibility